Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Update from the Clinic: November
Welcome to your Update from the Clinic for the month of November. There were a number of mid-stage clinical trials launched by cell-based immunotherapy companies this past month, furthering a robust global pipeline of CAR/TCR products. We also saw some efficacy data from StemCells, which reported positive interim results from its Phase 2 spinal cord […]
Cell Therapy Deal Review: September
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite Pharma expanded its relationship with the Netherlands Cancer Institute to develop […]
Cell Therapy Deal Review: August
. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a discovery grant to investigate NeukoPlastTM in prostate cancer. In other news we saw earnings reported, […]
Update from the Clinic: September
Welcome to your Update from the Clinic for the month of September. OncoSec Medical released some initial data from its Phase 1/2 study investigating ImmunoPulse IL-12 DNA in a rare skin cancer. Pluristem and the National Institute of Allergy and Infectious Diseases (NIAID) have agreed upon a trial design for Pluristem’s Phase 2 study investigating […]